HOOKIPA Pharma (HOOK) Competitors $0.83 +0.01 (+1.53%) As of 03:47 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOOK vs. COEP, ACRV, CALC, PLUR, JSPR, OVID, STTK, ALXO, FGEN, and PEPGShould you be buying HOOKIPA Pharma stock or one of its competitors? The main competitors of HOOKIPA Pharma include Coeptis Therapeutics (COEP), Acrivon Therapeutics (ACRV), CalciMedica (CALC), Pluri (PLUR), Jasper Therapeutics (JSPR), Ovid Therapeutics (OVID), Shattuck Labs (STTK), ALX Oncology (ALXO), FibroGen (FGEN), and PepGen (PEPG). These companies are all part of the "pharmaceutical products" industry. HOOKIPA Pharma vs. Its Competitors Coeptis Therapeutics Acrivon Therapeutics CalciMedica Pluri Jasper Therapeutics Ovid Therapeutics Shattuck Labs ALX Oncology FibroGen PepGen Coeptis Therapeutics (NASDAQ:COEP) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations. Do analysts recommend COEP or HOOK? HOOKIPA Pharma has a consensus target price of $4.50, suggesting a potential upside of 442.17%. Given HOOKIPA Pharma's stronger consensus rating and higher possible upside, analysts clearly believe HOOKIPA Pharma is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00HOOKIPA Pharma 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is COEP or HOOK more profitable? Coeptis Therapeutics has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -201.73% -108.46% HOOKIPA Pharma -785.66%-120.09%-77.14% Do institutionals & insiders hold more shares of COEP or HOOK? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, COEP or HOOK? Coeptis Therapeutics has higher earnings, but lower revenue than HOOKIPA Pharma. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.32HOOKIPA Pharma$9.35M1.08-$43.50M-$5.85-0.14 Does the media favor COEP or HOOK? In the previous week, HOOKIPA Pharma's average media sentiment score of 1.00 beat Coeptis Therapeutics' score of 0.68 indicating that HOOKIPA Pharma is being referred to more favorably in the news media. Company Overall Sentiment Coeptis Therapeutics Positive HOOKIPA Pharma Positive Which has more risk & volatility, COEP or HOOK? Coeptis Therapeutics has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Comparatively, HOOKIPA Pharma has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. SummaryHOOKIPA Pharma beats Coeptis Therapeutics on 10 of the 14 factors compared between the two stocks. Get HOOKIPA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOOK vs. The Competition Export to ExcelMetricHOOKIPA PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.12M$3.11B$5.74B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-0.1420.4030.4525.16Price / Sales1.08238.54392.5887.64Price / CashN/A42.3737.0358.50Price / Book0.207.918.956.21Net Income-$43.50M-$54.72M$3.26B$265.38M7 Day Performance-0.12%1.63%1.06%-1.13%1 Month Performance-20.19%5.86%4.31%-0.71%1 Year Performance-83.73%8.70%28.40%18.89% HOOKIPA Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOOKHOOKIPA Pharma3.325 of 5 stars$0.83+1.5%$4.50+442.2%-83.6%$10.12M$9.35M-0.14160Positive NewsCOEPCoeptis Therapeutics0.568 of 5 stars$11.06-0.9%N/A+217.0%$39.21MN/A-1.912News CoverageEarnings ReportShort Interest ↑ACRVAcrivon Therapeutics2.938 of 5 stars$1.23-0.8%$17.71+1,340.2%-85.6%$38.88MN/A-0.5558Analyst RevisionGap DownCALCCalciMedica3.2705 of 5 stars$2.76+0.7%$16.00+479.7%-28.6%$38.28MN/A-1.7730Short Interest ↓PLURPluri1.8758 of 5 stars$4.55-5.6%$12.00+163.7%-3.9%$37.91M$330K-0.82150Negative NewsShort Interest ↑Gap DownJSPRJasper Therapeutics2.9113 of 5 stars$2.63+7.3%$29.75+1,031.2%-84.8%$36.80MN/A-0.5020Analyst RevisionOVIDOvid Therapeutics4.2428 of 5 stars$0.56+7.9%$3.10+457.9%-15.9%$36.61M$570K-1.5960Short Interest ↑Analyst RevisionSTTKShattuck Labs3.5333 of 5 stars$0.74-2.3%$7.50+914.6%-69.4%$36.23M$5.72M-0.53100Earnings ReportAnalyst RevisionGap DownALXOALX Oncology2.7553 of 5 stars$0.61-9.2%$3.30+437.0%-66.9%$36.14MN/A-0.2540Gap UpFGENFibroGen4.606 of 5 stars$8.37-3.9%$43.00+413.7%+2.4%$35.20M$29.62M-3.35570Gap UpHigh Trading VolumePEPGPepGen3.0586 of 5 stars$1.01-5.6%$7.67+659.1%-87.4%$35.10MN/A-0.3430 Related Companies and Tools Related Companies Coeptis Therapeutics Competitors Acrivon Therapeutics Competitors CalciMedica Competitors Pluri Competitors Jasper Therapeutics Competitors Ovid Therapeutics Competitors Shattuck Labs Competitors ALX Oncology Competitors FibroGen Competitors PepGen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOOK) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HOOKIPA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HOOKIPA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access